Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study.

Published

Journal Article

Most pharmacotherapy trials in post-traumatic stress disorder (PTSD) have been conducted upon male combat veterans. Outcome studies relating to civilians are therefore needed.To demonstrate that fluoxetine is more effective than placebo in treating PTSD.Civilians with PTSD (n = 53) were treated for 12 weeks with fluoxetine (up to 60 mg/day) or placebo. Assessments of PTSD severity, disability, stress vulnerability, and high end-state function were obtained.Fluoxetine was more effective than placebo on most measures at week 12, including global improvement (much or very much improved: fluoxetine 85%, placebo 62%, difference 0.24, 95% CI 0.01-0.47; very much improved: fluoxetine 59%, placebo 19%, difference 0.40, 95% CI 0.16-0.64), and high end-state function (fluoxetine 41%, placebo 4%, difference 0.37, 95% CI 0.17-0.57).Fluoxetine was superior for measures of PTSD severity, disability, stress vulnerability, and high end-state function. The placebo-group response was low when viewed as a broad outcome based on a portfolio of ratings, but was higher with a traditional global rating criterion.

Full Text

Duke Authors

Cited Authors

  • Connor, KM; Sutherland, SM; Tupler, LA; Malik, ML; Davidson, JR

Published Date

  • July 1999

Published In

Volume / Issue

  • 175 /

Start / End Page

  • 17 - 22

PubMed ID

  • 10621763

Pubmed Central ID

  • 10621763

Electronic International Standard Serial Number (EISSN)

  • 1472-1465

International Standard Serial Number (ISSN)

  • 0007-1250

Digital Object Identifier (DOI)

  • 10.1192/bjp.175.1.17

Language

  • eng